Form 4: Clene Inc. CEO Robert Dee Etherington Acquires 25,000 Stock Options

Clene Inc.'s CEO, Robert Dee Etherington, reports the acquisition of 25,000 stock options at an exercise price of $5.15 per share.

Summary

• On August 16, 2024, Robert Dee Etherington, CEO of Clene Inc., acquired 25,000 stock options.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• The exercise price is $5.15 per share.
• The options vest in 1/12th increments monthly, starting September 16, 2024, until fully vested.
• The options expire on August 15, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The grant could be seen as a positive sign of confidence in the company's future, but it's not a major event.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of 1/12th monthly is a typical vesting arrangement.
• Comparing the size of the grant to similar companies would require further analysis of Clene Inc.'s compensation strategy and market capitalization.

Stakeholder Impact

• The stock option grant could potentially incentivize the CEO to improve company performance, benefiting shareholders.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates